跳至主要内容
临床试验/NCT01850056
NCT01850056已完成不适用

Prospective, Multi-center and Randomized Controlled Clinical Study to Verify Effectiveness and Safety of Drug-eluting Balloon in PTA Procedure (AcoArt I Study)

Acotec Scientific Co., Ltd10 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2013年4月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
200
试验地点
10
主要终点
Late Lumen Loss

研究概览

简要总结

The purpose of this study is to determine whether DEB is more effective than common PTA balloon in long-term vessel patency and inhibiting restenosis.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Age between 18 and 80 years
  • •Patients with peripheral artery disease (PAD), with Rutherford classification between 2 and 5
  • •an occlusion or a minimum grade of stenosisPrimary over 70% in the superficial femoral artery an /or the popliteal artery
  • •Total length of treat lesion(s)is less or equal to 40cm
  • •signed Patient informed consent form

排除标准

  • •plasma Cr level greater than 150 umol/L in patients
  • •patients with acute thrombosis requiring lysis or thrombectomy
  • •patient with a lysis or an lower limb intervention as a therapy within the last 6 weeks
  • •patient requiring intervention in both lower limbs at the same time
  • •target lesion can't be cross by the guide wire
  • •distal outflow through less than one lower leg vessel
  • •known hypersensitivity to aspirin, heparin, clopidogrel,paclitaxel, contrast medium, etc.
  • •patients participating in another clinical trials with interfere with this trial in the past 3 months
  • •pregnancy and lactating woman
  • •untreatable bleeding diatheses
  • •other diseases, such as cancer, liver disease, or cardiac insufficiency, which may lead to protocol violations or markedly shorten a patients's life expectancy(less than 2 years)
  • •patients unable or unwilling to participate this trial

研究组 & 干预措施

drug eluting balloon catheter

Experimental

use drug eluting balloon catheter to inflate the stenosis or occlusion in superficial femoral artery(SFA) and/or popliteal artery

干预措施: drug eluting balloon catheter (trade name: Orchid) (Device)

common balloon catheter(uncoated drug)

Active Comparator

use common balloon catheter to inflate stenosis or occlusion in SFA and/or popliteal artery

干预措施: common percutaneous transluminal angioplasty balloon catheter (trade name: Admiral) (Device)

结局指标

主要结局

Late Lumen Loss

时间窗: 6 months

measure difference of the MLD(minimal lumen diameter) at 0 time and 6 months

次要结局

  • major amputation(6 months, 12 months, 18 months, 24 months)
  • Minimal lumen diameter (MLD)(6 months)
  • change in ankle brachial index(ABI)(6 months)
  • change in Rutherford stage(6 months, 12 months, 18 months, 24 months)
  • Restenosis rate of target vessel(6 months, 12 months, 18 months, 24months)
  • target lesion revascularization(6 months, 12 months, 18 months, 24 months)
  • Death(12 months, 18 months, 24 months)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (10)

Loading locations...

相似试验